+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
GLENMARK

Glenmark Pharmaceuticals Share Price

 

 

Glenmark Pharmaceuticals live price: ₹2,235.50. It opened at ₹2,288 vs previous close ₹2,287; intraday high/low: ₹2,288/₹2,229. The 50 & 200 DMA stand at ₹2,232.80/₹2,096.00.

Glenmark Pharmaceuticals Performance

  • Today's Low
  • ₹2,229
  • Today's High
  • ₹2,288
  • 52 Week Low
  • ₹1,793
  • 52 Week High
  • ₹2,474
  • Open Price₹2,288
  • Previous Close₹2,287
  • Volume496,330
  • 50 DMA₹2,232.80
  • 100 DMA₹2,195.60
  • 200 DMA₹2,096.00

Glenmark Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 4.63%
  • Over 3 Month -0.62%
  • Over 6 Month + 11.74%
  • Over 1 Year + 0.4%

Smart Investing Starts Here Start SIP with Glenmark Pharmaceuticals for Steady Growth!

Invest Now

Glenmark Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 46.3
  • PEG Ratio
  • 1.5
  • Market Cap Cr
  • 63,086
  • P/B Ratio
  • 6
  • Average True Range
  • 56.6
  • EPS
  • 48.3
  • Dividend Yield
  • 0.2
  • MACD Signal
  • 17.5
  • RSI
  • 49.28
  • MFI
  • 76.43

Latest Stock News Updates

Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving Unaudited Financial Results Of Glenmark Pharmaceuticals Limited For The Quarter Ended June 30, 2026

Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter ended June 30, 2026

Stock to buy today: Glenmark Pharmaceuticals (2,270) BUY

Glenmark Pharmaceuticals share price can rise to 2,500

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single - Dose Vial

Glenmark Pharmaceuticals Financials

Glenmark Pharmaceuticals Technicals

EMA & SMA

Current Price
₹2,235.50
-51.4 (-2.25%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹2,245.20
  • 50 Day
  • ₹2,232.80
  • 100 Day
  • ₹2,195.60
  • 200 Day
  • ₹2,096.00

Resistance and Support

2250.8 Pivot Speed
  • R3 2,331.50
  • R2 2,309.70
  • R1 2,272.60
  • S1 2,213.70
  • S2 2,191.90
  • S3 2,154.80

Glenmark Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-31 Quarterly Results
2026-05-29 Audited Results & Final Dividend
2026-01-30 Quarterly Results
2025-11-14 Quarterly Results
2025-09-26 Interim Dividend
Date Purpose Remarks
2025-10-03 INTERIM Rs.2.50 per share(250%)Interim Dividend
2025-09-15 FINAL Rs.2.50 per share(250%)Final Dividend
View Glenmark Pharmaceuticals Dividend History Arrow
Date Purpose Remarks
2003-10-31 Split Stock Split From Rs 10/- per share to Rs 2/-

Glenmark Pharmaceuticals F&O

Glenmark Pharmaceuticals Shareholding Pattern

46.65%
20.89%
16.76%
13.81%
1.88%

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets. View More
  • NSE Symbol
  • GLENMARK
  • BSE Symbol
  • 532296
  • ISIN
  • INE935A01035

Similar Stocks to Glenmark Pharmaceuticals

Glenmark Pharmaceuticals FAQs

Glenmark Pharmaceuticals share price is ₹2,235 As on 18 July, 2026 | 10:11

The Market Cap of Glenmark Pharmaceuticals is ₹63086 Cr As on 18 July, 2026 | 10:11

The P/E ratio of Glenmark Pharmaceuticals is 46.3 As on 18 July, 2026 | 10:11

The PB ratio of Glenmark Pharmaceuticals is 6 As on 18 July, 2026 | 10:11

The 52 week High & Low of Glenmark Pharmaceuticals is ₹2474/₹1792.6 respectively As on 18 July, 2026 | 10:11

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23